Following positive results for its PD-1/L1 inhibitor Imfinzi (durvalumab) for stage III non-small cell lung cancer, AstraZeneca PLC believes that the major market opportunity for the drug will be its use even earlier on the treatment pathway.
Speaking to a small group of reporters at the weekend on the fringes of the European Society for Medical Oncology...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?